Erez Chimovits Biography and Net Worth

Director of Upstream Bio

Mr. Chimovits is a Partner at OrbiMed Advisors LLC. Chimovits has 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed, he was the CEO of NasVax. NasVax acquired Protea and struck agreements with GlaxoSmithKline and Novartis. Previously, Mr. Chimovits spent more than seven years with Compugen, as President, Compugen USA Inc. and Executive VP, Commercial Operations. At Compugen, he had P&L responsibility for more than 100 people and led multiple transactions including J&J, Novartis, Teva, Abbott, Medarex and others. Mr. Chimovits earned his MBA, MSc in Microbiology and his BSc from Tel Aviv University.

What is Erez Chimovits' net worth?: The estimated net worth of Erez Chimovits is at least $126.35 million as of October 15th, 2024. Mr. Chimovits owns 4,554,873 shares of Upstream Bio stock worth more than $126,352,177 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Chimovits may own. Learn More about Erez Chimovits' net worth.
How do I contact Erez Chimovits?: The corporate mailing address for Mr. Chimovits and other Upstream Bio executives is 890 Winter Street, Suite 200, Waltham, MA 02451, United States. Upstream Bio can also be reached via phone at (781) 208-2466 and via email at [email protected]. Learn More on Erez Chimovits' contact information.
Has Erez Chimovits been buying or selling shares of Upstream Bio?: Erez Chimovits has not been actively trading shares of Upstream Bio during the last ninety days. Most recently, on Tuesday, October 15th, Erez Chimovits bought 825,000 shares of Upstream Bio stock. The stock was acquired at an average cost of $17.00 per share, with a total value of $14,025,000.00. Following the completion of the transaction, the director now directly owns 4,554,873 shares of the company's stock, valued at $77,432,841. Learn More on Erez Chimovits' trading history.

Erez Chimovits Insider Trading History at Upstream Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/15/2024	Buy	825,000	$17.00	$14,025,000.00	4,554,873

Erez Chimovits Buying and Selling Activity at Upstream Bio

Upstream Bio Company Overview

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Today's Range

Now: $27.74

$26.69

$28.45

50 Day Range

MA: $23.19

$17.26

$28.98

2 Week Range

Now: $27.74

$5.14

$33.00

Volume

568,481 shs

Average Volume

482,285 shs

Market Capitalization

$1.50 billion

P/E Ratio

N/A

Dividend Yield